{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:32:27Z","timestamp":1776468747068,"version":"3.51.2"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"publisher","award":["2020\/37\/B\/NZ5\/02529"],"award-info":[{"award-number":["2020\/37\/B\/NZ5\/02529"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: Doxorubicin, a widely used chemotherapeutic agent, has been shown to increase reactive oxygen species (ROS) levels, disrupting cellular homeostasis not only in cancer cells but also in healthy tissues, particularly in cardiomyocytes, which leads to chemotherapy-induced cardiotoxicity. Therefore, new strategies are continually being explored to mitigate these adverse effects. One such approach is the use of additional substances with cardioprotective properties during doxorubicin therapy. A promising candidate is elabela, a peptide of the apelinergic system, which may exert protective effects against doxorubicin-induced oxidative stress in cardiomyocytes. Objectives: This study aims to evaluate the modulatory effects of elabela on oxidative stress markers, malondialdehyde (MDA) and 8-hydroxy-2\u2032-deoxyguanosine (8-OHdG) in the left ventricle of the myocardium following chronic doxorubicin administration in rats. Material and Methods: 32 male, 12-week-old Sprague-Dawley rats (SPRD) were randomly assigned to four experimental groups. For 28 days, all animals received continuous infusions (2.5 \u03bcL\/h) via subcutaneously implanted osmotic pumps of 0.9% NaCl or elabela (40 \u03bcg\/kg body weight\/day or 200 \u03bcg\/kg body weight\/day). Simultaneously, animals were injected intraperitoneally 4 times at weekly intervals with 0.9% NaCl or DOX (3.5 mg\/kg body weight). Next, the animals were sacrificed, and left ventricular (LV) cardiac tissue was collected for further analysis. MDA and 8-OHdG and elabela level in LV lysate were assessed by ELISA. The Ela expression in LV was quantified by Real-Time PCR. The TUNEL assay, labeled with a 5\u2032-triphosphate strand, was used to assess the degree of apoptosis. Results: DOX treatment decreased both the Ela expression and elabela levels in the LV. Elabela administration at a dose of 200 \u00b5g\/kg body weight\/day significantly decreased ELA levels and Ela expression compared to the control group. The level of 8-OhdG was unexpectedly decreased in the DOX group compared to controls, while elabela treatment at both doses restored 8-OHdG levels observed in the control group. However, TUNEL staining demonstrated that elabela administration at 200 \u00b5g\/kg body weight\/day reduced the number of apoptotic cardiomyocytes compared to the DOX-only group, indicating a protective effect against DOX-induced apoptosis. The lower dose of 40 \u00b5g\/kg body weight\/day showed a moderate, non-significant attenuation of apoptosis. Conclusions: Elabela showed a protective effect against DOX-induced cardiomyocyte apoptosis in the LV by promoting processes that reduce oxidative stress in cardiac cells.<\/jats:p>","DOI":"10.3390\/biomedicines13102407","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:38:55Z","timestamp":1759246735000},"page":"2407","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elabela Attenuates Doxorubicin-Induced Oxidative DNA Damage and Apoptosis in Rat Left Ventricular Myocardium"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6574-4049","authenticated-orcid":false,"given":"Katarzyna","family":"Matusik","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kami\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-8401","authenticated-orcid":false,"given":"Izabela","family":"Janiuk","sequence":"additional","affiliation":[{"name":"Department of Histology and Embryology, Center of Biostructure Research, Medical University of Warsaw, Cha\u0142ubi\u0144skiego 5, 02-004 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-0975","authenticated-orcid":false,"given":"Kaja","family":"Kasare\u0142\u0142o","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1116-7327","authenticated-orcid":false,"given":"Maja","family":"Owe-Larsson","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"},{"name":"Department of Histology and Embryology, Center of Biostructure Research, Medical University of Warsaw, Cha\u0142ubi\u0144skiego 5, 02-004 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Dylko","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Cudnoch-J\u0119drzejewska","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0148607111434963","article-title":"Oxidative stress","volume":"36","author":"Preiser","year":"2012","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/jcrt.JCRT_862_16","article-title":"Oxidative stress and its role in cancer","volume":"17","author":"Jelic","year":"2021","journal-title":"J. Cancer Res. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.numecd.2005.05.003","article-title":"A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress","volume":"15","author":"Stewart","year":"2005","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_4","first-page":"120","article-title":"Fiotakis C8-hydroxy-2\u2032 -deoxyguanosine (8-OHdG): Acritical biomarker of oxidative stress carcinogenesis","volume":"27","author":"Valavanidis","year":"2009","journal-title":"J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/0192623309356453","article-title":"Oxidative stress and oxidative damage in carcinogenesis","volume":"38","author":"Klaunig","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI21625","article-title":"Increased oxidative stress in obesity and its impact on metabolic syndrome","volume":"114","author":"Furukawa","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Reddy, V.P. (2023). Oxidative Stress in Health and Disease. Biomedicines, 11.","DOI":"10.3390\/biomedicines11112925"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wu, B.B., Leung, K.T., and Poon, E.N. (2022). Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031912"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","article-title":"Doxorubicin: Nanotechnological overviews from bench to bedside","volume":"22","author":"Cagel","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0891-5849(02)01016-X","article-title":"Relative contributions of heart mitochondria glutathione peroxidase and catalase to H(2)O(2) detoxification in in vivo conditions","volume":"33","author":"Antunes","year":"2002","journal-title":"Free Radic. Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"107683","DOI":"10.1016\/j.carpath.2024.107683","article-title":"Doxorubicin-related cardiotoxicity: Review of fundamental pathways of cardiovascular system injury","volume":"73","author":"Avagimyan","year":"2024","journal-title":"Cardiovasc. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"46663","DOI":"10.18632\/oncotarget.16944","article-title":"Autophagy and mitophagy in the context of doxorubicin-induced cardiotoxicity","volume":"8","author":"Koleini","year":"2017","journal-title":"Oncotarget"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25535","DOI":"10.1074\/jbc.M400944200","article-title":"Doxorubicin induces apoptosis in normal tumor cells via distinctly different mechanisms intermediacy of H2O2-, p53-dependent pathways","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Avagimyan, A., Pogosova, N., Rizzo, M., and Sarrafzadegan, N. (2025). Doxorubicin-induced cardiometabolic disturbances: What can we do?. Front. Clin. Diabetes Healthc., 6.","DOI":"10.3389\/fcdhc.2025.1537699"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alwaili, M.A., Abu-Almakarem, A.S., El-Said, K.S., Eid, T.M., Mobasher, M.A., Alsabban, A.H., Alburae, N.A., Banjabi, A.A., and Soliman, M.M. (2025). Shikimic acid protects against doxorubicin-induced cardiotoxicity in rats. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-90549-4"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Monserrat-Mesquida, M., Quetglas-Llabres, M., Capo, X., Bouzas, C., Mateos, D., Pons, A., Tur, J.A., and Sureda, A. (2020). Metabolic Syndrome is Associated with Oxidative Stress and Proinflammatory State. Antioxidants, 9.","DOI":"10.3390\/antiox9030236"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/ajh.2011.202","article-title":"Impact of cardiovascular risk factors inflammatory status on urinary 8-OHdGin essential hypertension","volume":"25","author":"Morillas","year":"2012","journal-title":"Am. J. Hypertens."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10741-024-10414-w","article-title":"The significance of the apelinergic system in doxorubicin-induced cardiotoxicity","volume":"29","author":"Matusik","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101882","DOI":"10.1016\/j.jsps.2023.101882","article-title":"Protective effect of coenzyme Q10 against doxorubicin-induced cardiotoxicity: Scoping review article","volume":"32","year":"2024","journal-title":"Saudi Pharm. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116794","DOI":"10.1016\/j.taap.2023.116794","article-title":"Resveratrol protects against doxorubicin-induced cardiotoxicity by attenuating ferroptosis through modulating the MAPK signaling pathway","volume":"482","author":"Chen","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.toxlet.2019.01.014","article-title":"Apelin-13 reduces oxidative stress induced by uric acid via downregulation of renin-angiotensin system in adipose tissue","volume":"305","author":"Zhang","year":"2019","journal-title":"Toxicol. Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.peptides.2013.05.006","article-title":"Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction","volume":"46","author":"Azizi","year":"2013","journal-title":"Peptides"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"108822","DOI":"10.1016\/j.intimp.2022.108822","article-title":"Apelin\/APJ system in inflammation","volume":"109","author":"Wang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2796.1999.00480.x","article-title":"QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin\u2032s lymphoma","volume":"245","author":"Nousiainen","year":"1999","journal-title":"J. Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/atm.2020.02.07","article-title":"Apelin\/Elabela-APJ: A novel therapeutic target in the cardiovascular system","volume":"8","author":"Liu","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106186","DOI":"10.1016\/j.phrs.2022.106186","article-title":"Elabela ameliorates doxorubicin-induced cardiotoxicity by promoting autophagic flux through TFEB pathway","volume":"178","author":"Chen","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, X., Zhang, L., Feng, M., Xu, Z., Cheng, Z., and Qian, L. (2022). ELA-11 protects the heart against oxidative stress injury induced apoptosis through ERK\/MAPK and PI3K\/AKT signaling pathways. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.873614"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1042\/CS20200301","article-title":"Molecular mechanisms of anthracycline cardiovascular toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mce.2016.07.040","article-title":"Agonist-induced internalization and desensitization of the apelin receptor","volume":"437","author":"Pope","year":"2016","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_31","first-page":"4467","article-title":"Elabela alleviates myocardial ischemia reperfusion-induced apoptosis fibrosis mitochondrial dysfunction through PI3K\/AKTsignaling","volume":"12","author":"Yu","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ma, W., Wei, S., Zhang, B., and Li, W. (2020). Molecular Mechanisms of Cardiomyocyte Death in Drug-Induced Cardiotoxicity. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00434"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jcmm.16052","article-title":"Elabela may regulate SIRT3-mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic-induced myocardial injury","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2559.2011.03954.x","article-title":"An easy cell counting method for immunohistochemistry that does not use an image analysis program","volume":"59","year":"2011","journal-title":"Histopathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","article-title":"Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies","volume":"52","author":"Octavia","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2003.11.001","article-title":"Oxidative DNA damage and disease: Induction, repair and significance","volume":"567","author":"Evans","year":"2004","journal-title":"Mutat. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1600-0773.2003.930301.x","article-title":"Doxorubicin-induced cardiac mitochondrionopathy","volume":"93","author":"Wallace","year":"2003","journal-title":"Pharmacol. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Demirci-\u00c7eki\u00e7, S., \u00d6zkan, G., Avan, A.N., Uzunboy, S., \u00c7apano\u011flu, E., and Apak, R. (2022). Biomarkers of oxidative stress and antioxidant defense. J. Pharm. Biomed. Anal., 209.","DOI":"10.1016\/j.jpba.2021.114477"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.mrrev.2014.11.002","article-title":"Oxidatively induced DNA damage and its repair in cancer","volume":"763","author":"Dizdaroglu","year":"2015","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"key":"ref_40","first-page":"3","article-title":"Cardio-oncology: Chances and challenges","volume":"120","year":"2025","journal-title":"Basic Res. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Aloss, K., and Hamar, P. (2023). Recent Preclinical and Clinical Progress in Liposomal Doxorubicin. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030893"},{"key":"ref_42","first-page":"322","article-title":"Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: JACC: CardioOncology Controversies in Cardio-Oncology","volume":"6","author":"Upshaw","year":"2024","journal-title":"Cardio Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","volume":"27","author":"Sobczuk","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.arr.2023.102076","article-title":"A promising therapeutic peptide and preventive\/diagnostic biomarker for age-related diseases: The Elabela\/Apela\/Toddler peptide","volume":"91","author":"Monastero","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Buczma, K., Borzuta, H., Kaminska, K., Sztechman, D., Matusik, K., Pawlonka, J., Kowara, M., Buchalska, B., and Cudnoch-J\u0119drzejewska, A. (2025). Apelinergic System Affects Electrocardiographic Abnormalities Induced by Doxorubicin. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010094"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"131331","DOI":"10.1016\/j.ijcard.2023.131331","article-title":"Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy","volume":"391","author":"Avagimyan","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"107526","DOI":"10.1016\/j.vph.2025.107526","article-title":"Translational aspects of doxorubicin-induced cardiotoxicity: What we have omitted for the past decades?","volume":"160","author":"Avagimyan","year":"2025","journal-title":"Vasc. Pharmacol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2407\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:10:38Z","timestamp":1760501438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102407"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102407","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}